2026 Physician Fee Schedule Impact on Dermatology: CF Increase, Skin Substitutes & Efficiency Cuts

The CY 2026 Physician Fee Schedule Final Rule introduces reimbursement changes that every dermatology practice needs to understand. The headline is a 3.26% conversion factor increase, but a new 2.5% efficiency adjustment partially offsets the gain. Combined with the skin substitute reclassification, the net impact on dermatology revenue is complex.

The Conversion Factor: Up 3.26%, But…

CMS increased the conversion factor (CF) for most clinicians by 3.26% for 2026. However, a new 2.5% efficiency adjustment reduces payments for many procedure codes. The net effect for most dermatology services is a modest increase of approximately 0.7-1.0%.

Skin Substitute Reclassification

The biggest financial impact for dermatology is the reclassification of skin substitutes from drugs/biologicals to “wound care management products.” Reimbursement shifts from the ASP-based method to a flat-fee “incident-to supply” payment of $127.28 per square centimeter.

This site-neutral policy reduces per-application payments for most products and requires clear documentation of medical necessity, appropriateness, and frequency. Read our full skin substitute guide →

What This Means for Your Practice

Winners

• E/M visits (99202-99215) see a modest reimbursement increase
• SRT may see higher reimbursement under new OPPS-based valuation
• Mohs surgery codes are relatively unaffected

Losers

• Skin substitute applications — significant margin compression
• High-volume destruction codes — efficiency adjustment reduces per-unit payment
• Practices heavily reliant on CTP revenue — business model at risk

Action Items

1. Update your fee schedules with the new CF and efficiency-adjusted rates
2. Recalculate skin substitute profitability under the new flat-rate model
3. Review your procedure mix — shift toward higher-margin services where clinically appropriate
4. Renegotiate commercial contracts using the Medicare rate changes as a benchmark